select ad.sno,ad.journal,ad.title,ad.author_names,ad.abstract,ad.abstractlink,j.j_name,vi.* from articles_data ad left join journals j on j.journal=ad.journal left join vol_issues vi on vi.issue_id_en=ad.issue_id where ad.sno_en='8814' and ad.lang_id='3' and j.lang_id='3' and vi.lang_id='3' Successful Treatment of Intravenous Immunoglobulins in a Pat | 8814
Журнал клинических и экспериментальных дерматологических исследований

Журнал клинических и экспериментальных дерматологических исследований
Открытый доступ

ISSN: 2155-9554

Абстрактный

Successful Treatment of Intravenous Immunoglobulins in a Patient with Intractable Epidermolysis Bullosa Acquisita with Autoantibodies to Type VII Collagen and Laminin Alpha-3

Shin-Ichi Osada, Rui Yoshida, Izumi Kikuchi, Daisuke Tsuruta, Shin-ichi Ansai, Takashi Hashimoto and Seiji Kawana

Epidermolysis bullosa acquisita (EBA) is a blistering disease caused by autoantibodies to type VII collagen, a major component of anchoring fibrils at the dermal-epidermal junction. Here, we report a case of inflammatory EBA with a unique antibody prolife showing reactivity to laminin alpha-3 as well as type VII collagen. The patient’s cutaneous lesions were refractory to dapsone, prednisolone, betamethasone, and double filtration plasmapheresis, which led to a catheter-mediated methicillin-resistant staphylococcal aureus (MRSA) sepsis. Intravenous immunoglobulins (IVIG) initially used to resolve MRSA sepsis improved the pruritus and skin manifestations of EBA, and clinical remission of EBA was achieved after only two cycles of IVIG. The mechanism for the concurrence of antibodies to type VII collagen and laminin alpha-3 and the potential mode of action of IVIG in EBA are discussed.

Отказ от ответственности: Этот тезис был переведен с использованием инструментов искусственного интеллекта и еще не прошел рецензирование или проверку.
Top
https://www.olimpbase.org/1937/